Symbiotec Pharmalab sets Rs 938-988 band for Rs 1,757 crore IPO

The Development

Symbiotec Pharmalab Limited, an Indore-based pharmaceutical and active-pharmaceutical-ingredient (API) maker, has set a price band of Rs 938 to Rs 988 per share for its initial public offering, which opens for subscription on 24 August 2026 and closes on 27 August 2026. At the upper end of the band the issue is sized at about Rs 1,757 crore, according to the price-band announcement reported by The Economic Times. The offer is a mainboard issue and is scheduled to list on the NSE and the BSE on 1 September 2026, with the basis of allotment expected to be finalised on 28 August.

The offering combines a fresh issue of shares with an offer for sale by existing shareholders. Symbiotec's draft red herring prospectus filed with SEBI was lodged in December 2025 and sits on the regulator's public-issues record. A company may proceed to its public offer only after SEBI issues its observations on the draft, a step that is a clearance to proceed and not an endorsement of the issue, its price or its merits. The announced band and calendar mark the point at which the offer's commercial terms become operative.

The Company

Per the DRHP, Symbiotec Pharmalab describes itself as "a research and development-driven, science-based pharmaceutical and biotechnology company" with capabilities across organic chemistry, biotechnology and complex injectables. The company discloses that it makes corticosteroid and steroidal-hormone APIs and also operates as a contract development and manufacturing organisation (CDMO). Its registered and corporate office is at Pigdamber, Rau, near Indore in Madhya Pradesh, and its manufacturing operations are located in that state.

On scale, the DRHP cites third-party industry research placing Symbiotec's global volume market share at 36.2% in corticosteroid APIs and 44.2% in steroidal-hormone APIs in FY2025. The company presents this positioning as central to its business, which supplies regulated and semi-regulated markets.

On financials, the company discloses restated consolidated revenue from operations of Rs 716.25 crore in FY2024 and Rs 751.55 crore in FY2025, with profit after tax of Rs 100.06 crore and Rs 96.79 crore respectively. For the three months to 30 June 2025 (the first quarter of FY2026), the DRHP reports revenue from operations of Rs 203.17 crore and profit after tax of Rs 29.92 crore. The company discloses net worth of Rs 821.15 crore and total borrowings of Rs 540.92 crore as at 31 March 2025, and basic earnings per share of Rs 17.70 for FY2025.

The Offer Structure

Per the announcement, the offer comprises a fresh issue of Rs 150 crore and an offer for sale, together sized at about Rs 1,757 crore at the upper band. The DRHP named three selling shareholders for the offer-for-sale portion: the promoter entity Satwani Holdings LLP and the investor shareholders Rosewood Investments and India Business Excellence Fund III. Because offer-for-sale proceeds flow to the selling shareholders, the company itself receives only the fresh-issue proceeds.

The stated objects of the fresh issue, per the DRHP, are the prepayment or repayment of certain borrowings of Rs 112.50 crore and general corporate purposes. The book-running lead managers to the offer are JM Financial, Avendus Capital, Motilal Oswal Investment Advisors and Nomura Financial Advisory and Securities (India); the registrar is MUFG Intime India. The lot size is 15 shares, taking the minimum retail application to Rs 14,820 at the upper band. Under the DRHP's eligibility route, not more than 50% of the offer is available to qualified institutional buyers, not less than 15% to non-institutional investors and not less than 35% to retail investors. Readers working through the arithmetic of an allotment can use Oquilia's lumpsum calculator or CAGR calculator, and prior primary-market coverage sits on the Oquilia news desk.

Risk Factors

The following risks are drawn from the risk-factors section of Symbiotec's DRHP and are what the company itself was required to disclose; they are not this desk's assessment. The RHP lists geographic concentration: the company's manufacturing facilities are located in Madhya Pradesh, so disruption in that state could affect operations. The company discloses customer concentration, stating it derives a substantial portion of its revenue from certain key customers.

Among the risk factors the company discloses, it also flags dependence on imported raw materials, including procurement from countries such as China, and reliance on a limited set of suppliers. The DRHP notes that its manufacturing facilities are subject to periodic inspections and audits by regulatory authorities, an adverse outcome of which could affect approvals. The company further discloses product-liability exposure tied to its corticosteroid and steroidal-hormone APIs. The DRHP's auditors' examination report additionally records certain matters of emphasis, and the document discloses that some corporate records are not traceable.

What Happens Next

The offer follows the standard mainboard sequence from here. Anchor-investor bidding takes place one working day before the issue opens, ahead of the 24 August start; the three-day subscription window then runs to 27 August, with bids placed through the ASBA and UPI mechanism under which application money is blocked rather than debited. Exchange bid data is published category-wise through the window.

After the close, the basis of allotment is expected to be finalised on 28 August, per the announced calendar, with refunds or the unblocking of application money following for unsuccessful or partially successful bids. Shares are then credited to demat accounts ahead of listing, scheduled for 1 September on the NSE and the BSE. Each of these dates is a matter of the offer's timetable and not a forecast of demand or price.

FAQ

Should I apply for this IPO?

Oquilia does not make recommendations. This report is informational and is not investment advice or a recommendation to subscribe. The RHP, including the complete risk-factors section, is available on SEBI's website and the exchanges - read it directly before making any decision.

What is the price band and lot size?

Per the price-band announcement, the band is Rs 938 to Rs 988 per share and the lot size is 15 shares, so a single retail lot needs Rs 14,820 at the upper band. Bids above the minimum are placed in multiples of the lot size, per the offer's terms.

When does the issue open and close?

The subscription window runs from 24 August to 27 August 2026, per the announced calendar. Anchor allocation takes place one working day before the open, the basis of allotment is expected on 28 August, and listing is scheduled for 1 September on the NSE and BSE.

What do SEBI's observations mean?

SEBI reviews a draft offer document and issues observations before a company may launch its offer. Observations are a clearance to proceed and, per SEBI's standard position, do not amount to approval of the issue, its price or its merits. The regulator does not vouch for the accuracy of the document.

Where can I read the RHP?

The draft red herring prospectus is on SEBI's public-issues record, and the final offer document is filed with SEBI and the exchanges. The links appear in the source line below. The document carries the full financial statements, the stated objects and the complete risk-factors section.

This report is based on the draft red herring prospectus filed with SEBI and on the Symbiotec Pharmalab price-band announcement reported by The Economic Times.